PDCD1 and neoplasm: We evaluated this combination in the AT3OVA model and show that the combination of reduced doses olaparib, AZD1775 and anti-PD-1 significantly improved survival and tumour growth control compared to the combined olaparib and AZD1775 treatment group (p < 0.001; Fig. 3c).